Arsenic Trioxide Targets miR-125b in Glioma Cells

Title:Arsenic Trioxide Targets miR-125b in Glioma Cells

Volume: 20 Issue: 33

Author(s): Sulian Chen, Lihua Zhu, Jing Huang, Ying Cai, Xiaohui Lu, Qingling Yang, Qiong Wu, Changjie Chen and Zhiwei Wang

Affiliation:

Keywords: As₂O₃, glioma, invasion, miR-125b, Bak1.

Abstract: Background: Arsenic trioxide (As₂O₃) has been demonstrated to suppress tumorigenesis in human glioma. However, the exact molecular mechanisms by which As₂O₃ exerts its tumor suppressor functions are elusive. Therefore, it is warranted to explore the underlying mechanism of As₂O₃–mediated anti-tumor activity in glioma.

Methods: To achieve our goal, we used multiple approaches including MTT assay, apoptosis, Real-time RT-PCR, Western blotting, invasion assay, and gene transfection.

Results: We observed that A₂2O₃ inhibited cell growth and induced apoptosis as well as suppressed migration and invasion in human glioma cells. Moreover, we found that As₂O₃ down-regulated miR-125b expression and subsequently up-regulated its target gene Bak1 expression. Furthermore, we identified that As₂O₃ exerts its anti-tumor activity partly through regulation of miR-125b.

Conclusions: Our present study suggests that As₂O₃ could be a potential therapeutic agent for treatment of human glioma.

Cite this article as:

Chen Sulian, Zhu Lihua, Huang Jing, Cai Ying, Lu Xiaohui, Yang Qingling, Wu Qiong, Chen Changjie and Wang Zhiwei, Arsenic Trioxide Targets miR-125b in Glioma Cells, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128204132